Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Phase Ib and II Open-Label, Multi-Center Study of MEDI4736 Evaluated in Different Combinations in Patients With Metastatic Pancreatic Ductal Adenocarcinoma

Next Previous
Trial Profile

A Phase Ib and II Open-Label, Multi-Center Study of MEDI4736 Evaluated in Different Combinations in Patients With Metastatic Pancreatic Ductal Adenocarcinoma

Status: Completed
Phase of Trial: Phase I/II

Latest Information Update: 16 Aug 2019

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Durvalumab (Primary) ; AZD 5069; Gemcitabine; Paclitaxel
  • Indications Adenocarcinoma; Pancreatic ductal carcinoma
  • Focus Adverse reactions; Therapeutic Use
  • Sponsors AstraZeneca

Most Recent Events

  • 20 Jul 2018 Status changed from active, no longer recruiting to completed.
  • 03 Jul 2018 Planned End Date changed from 2 Apr 2018 to 3 Jul 2018.
  • 03 Jul 2018 Planned primary completion date changed from 2 Apr 2018 to 3 Jul 2018.

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top